Fortesta

Quick links to important sections

Fortesta

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fortesta

Property Description
Active Ingredient Testosterone
Form Transdermal Gel (Metered-dose Pump)
Pharmacological Class Androgen Replacement Therapy (ART)
Common Use Treatment of male hypogonadism
Origin Synthetic (Steroid hormone preparation)

Fortesta is a specialized, prescription-only medication classified as an androgen indicated for replacement therapy in adult males. This places it within the therapeutic class of Androgen Replacement Therapy (ART), a specific form of Hormone Replacement Therapy (HRT). Fortesta is used to address the deficiency or complete absence of endogenous testosterone, a condition commonly known as hypogonadism. The necessity of replacement therapy for symptomatic hypogonadism is clinically recognized. This means the medication directly supplies the necessary hormone to correct the deficiency.

Composition and Drug Form: The Transdermal Gel

The sole active ingredient in Fortesta is Testosterone, which is chemically defined as an androstanoid and a C19 steroid. This pharmaceutical is a synthetic preparation designed to replace the naturally produced hormone. Fortesta is supplied as a transdermal gel preparation dispensed from a metered-dose pump, designed for topical use on the skin. The use of a metered-dose pump is a differentiating feature intended to enhance dosing accuracy. This single-ingredient product is formulated in a hydroalcoholic gel base, which serves as the vehicle for delivering the androgen for systemic absorption.

The General Benefit of Testosterone Supplementation

The general clinical objective of Fortesta is to provide necessary hormone supplementation to restore and maintain the body's serum testosterone levels to a normal, therapeutic range. This controlled, transdermal supply mechanism supports the long-term stability of the androgen concentration. This restoration is the foundational benefit for managing the physiological consequences associated with confirmed testosterone deficiency. The consistent delivery provided by the transdermal route is medically noted for establishing stable serum concentrations, which is essential for effective long-term management. This stability helps ensure the hormone levels remain in the appropriate range throughout the day.

What side effects are possible with Fortesta?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety characteristics of Fortesta (Testosterone Transdermal Gel) as classified by regulatory authorities.

Safety data categorizes documented adverse reactions by frequency and physiological system. Common effects, reported in clinical trials, include application site reactions (such as redness or irritation), increases in Prostatic Specific Antigen (PSA), polycythemia (elevated red blood cell count), headache, and gynecomastia (breast enlargement). Less frequently reported effects are classified as uncommon, which include acne, dizziness, and insomnia.

Regulatory documents highlight the potential for serious adverse reactions. These include the risk of Venous Thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism, and the potential for the onset or worsening of sleep apnea. Testosterone replacement therapy is associated with the possibility of developing or exacerbating prostate conditions, including benign prostatic hyperplasia and prostate cancer. Therefore, periodic monitoring of the prostate and PSA is required during long-term use.

Safety-Related Restrictions prohibit the use of this medication in men with known or suspected carcinoma of the breast or prostate. Special consideration is advised for specific populations; for instance, patients with pre-existing severe cardiac, renal, or hepatic impairment face an increased risk of fluid retention and edema. The transdermal application carries a known risk of secondary exposure, where women or children may inadvertently absorb the medication from the unwashed application site, potentially resulting in adverse hormonal effects.

Overdose and Emergency Response

The official regulatory profile for Fortesta overdose is structured around recognizing signs of severe hormonal excess and the resulting life-threatening outcomes. Overdosage may be associated with symptoms indicating serious cardiovascular or neurological events. Documented manifestations include severe or sudden headache, seizures, blurred vision, slurred speech, and sudden weakness in the arm or leg. These manifestations require immediate medical attention.

Urgent medical help must be sought if any symptoms consistent with a major adverse event are experienced, such as chest pain, sudden difficulty breathing, or collapse. The mandated management for established overexposure is symptomatic and supportive treatment, as regulatory documents confirm that no specific antidote is known for testosterone overdose.

If laboratory tests show that serum testosterone concentrations consistently exceed the normal therapeutic range, the official instruction is to either discontinue therapy entirely or decrease the daily dose of the gel. A specific population consideration involves unintentional secondary exposure in children or women, which may lead to toxicity classified as virilization. In such cases, regulators mandate the prompt discontinuation of the testosterone gel until the cause of the reaction is identified.

Therapeutic Uses of Fortesta

Fortesta is an androgen replacement medication commonly used for adult men with clinically significant hypogonadism—a deficiency or complete absence of naturally produced testosterone. The medication is applied in addressing situations where this hormonal deficit leads to a cluster of disruptive symptoms. The goal of this therapy is to help address systemic imbalance by supporting normalization of testosterone levels, provided the diagnosis is confirmed by laboratory tests. This therapy is commonly used to help with conditions that present with systemic or localized discomfort, including diminished muscle mass and strength, low sexual desire (libido), and chronic fatigue. It can assist with maintaining functional stability when symptoms interfere with routine activities.


Management of Hormonal and Symptomatic Burden

The medication is relevant in clinical settings that involve chronic, unstable symptom patterns resulting from Primary hypogonadism or Hypogonadotropic hypogonadism. By providing necessary hormonal supplementation, Fortesta supports the management of physical symptoms related to decline, is used for managing chronic fatigue, and contributes to supporting motivation and a sense of stability. This provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Sexual Function Deficits Fortesta is relevant for easing symptoms that cluster around low libido and erectile function when these are directly linked to hormone deficiency.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Fortesta

Regulatory documentation defines strict patient population limits for Fortesta use, classifying groups as either indicated, restricted, or contraindicated.

Category Official Regulatory Statement
Populations for whom use is allowed Adult males with a confirmed diagnosis of primary or hypogonadotropic hypogonadism.
Populations for whom use is contraindicated Men with carcinoma of the breast or known or suspected carcinoma of the prostate.
Populations for whom use is contraindicated Women who are pregnant, may become pregnant, or who are breastfeeding.

Age-Related Eligibility Rules

The safety and efficacy of Fortesta have not been established for use in males less than 18 years old. Similarly, use is not established in men with so-called “age-related hypogonadism.” There are insufficient long-term safety data in older adults to fully assess certain risks, such as cardiovascular disease.

Condition-Specific Use Restrictions

The medicine is not recommended for men with uncontrolled hypertension. Additionally, the label advises caution for patients with pre-existing severe cardiac, renal, or hepatic disease due to the potential for fluid retention and edema. Patients with benign prostatic hyperplasia (BPH) require monitoring for worsening symptoms.

What should I know about interactions with other medicines?

The official regulatory documentation for Fortesta defines interaction patterns with three principal classes of co-administered medicines. The product information does not document any mandatory timing separation rules between the gel application and other oral medications, nor does it list specific interactions with food, alcohol, or herbal products in the dedicated Drug Interactions section.

Interactions Requiring Specific Monitoring or Adjustment

Co-administration with Oral Anticoagulants is a documented interaction that may result in changes to the anticoagulant activity of the co-administered medicine. The official regulatory labeling mandates more frequent laboratory monitoring of the patient’s International Normalized Ratio (INR) and Prothrombin Time to safely manage this potential effect.

A pharmacodynamic interaction is also documented with Insulin and other Antidiabetic Agents. The use of testosterone may decrease blood glucose levels, which can subsequently reduce the required dosage of the antidiabetic medicine. This necessitates close monitoring to manage blood sugar stability.

Interactions Affecting Fluid Balance

Concurrent use with Corticosteroids or Adrenocorticotropic Hormone (ACTH) is officially noted to carry an additive effect that increases the risk of fluid retention (edema). This specific interaction is considered particularly significant in patients who have pre-existing conditions such as cardiac, renal, or hepatic disease. No specific medication is formally documented as contraindicated for co-administration due to interaction risk.

Mechanism of Action

Fortesta, a transdermal testosterone preparation, delivers the androgen directly into the systemic circulation, where it circulates bound primarily to sex hormone-binding globulin (SHBG) and albumin. The unbound fraction is biologically active. Testosterone acts as an agonist at the intracellular Androgen Receptor (AR), a ligand-activated transcription factor found in target tissues.

Upon ligand binding, the testosterone-AR complex dissociates from heat shock proteins, translocates to the cell nucleus, and binds to specific DNA sequences known as Androgen Response Elements (AREs). This binding modulates the transcription of target genes. Furthermore, testosterone is metabolized by the enzyme 5alpha-reductase into its more potent metabolite, dihydrotestosterone (DHT), which also functions as an AR agonist with higher binding affinity. System-level consequences include the modulation of protein anabolism, nitrogen retention, and the suppression of the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback, which decreases the pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Dosage and Administration Information

Fortesta is administered via the topical, transdermal route as a gel applied exclusively to the front and inner thighs. This medicine is used as a once-daily regimen, with application ideally performed in the morning. The drug is supplied in a metered-dose pump, where each actuation delivers 10 mg of testosterone. The preparation requires a mandatory initial step: the pump must be primed with eight full actuations before the first use to ensure accurate metering, with the discharged gel safely discarded.

The standard labeled dosing for adult males begins at 40 mg of testosterone (four pump actuations) once daily. The daily quantity may be adjusted between a minimum of 10 mg and a maximum of 70 mg (seven actuations). This dose adjustment, or titration, is structurally defined in the official protocol: it is based on measured serum testosterone concentrations taken from a blood draw conducted two hours after application. These assessments are scheduled for approximately 14 days and 35 days after initiating treatment or changing the dose, establishing the long-term use protocol. Use of the gel is restricted to adult males, as the safety and efficacy patterns are not established for individuals under 18 years of age.

Following administration, specific procedural steps are required, including immediately washing hands and covering the application site once the gel has dried. Additionally, washing, swimming, or showering at the application site must be avoided for at least two hours to support correct systemic delivery.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fortesta

Research Evidence for Confirmed Male Hypogonadism

The official evaluation of Fortesta (testosterone transdermal gel) examined the use of the drug in confirmed male hypogonadism, which is a condition involving the deficiency or complete absence of naturally produced testosterone. The evidence base primarily involves one pivotal, short-term, open-label Phase III trial, alongside other supporting pharmacokinetic (PK) studies. The trials included adult males who had a laboratory-confirmed diagnosis of either primary or hypogonadotropic hypogonadism.

Research explored the potential for biomarker shifts, with the main goal of the pivotal trial being to measure the percentage of participants who achieved serum testosterone concentration within the normal physiological range over a defined time interval. The studies monitored the stability of these hormone levels, providing research that describes the short-term changes observed in the trial population.

Focus of Study Outcomes: Hormonal and Pharmacokinetic Data

The primary outcomes studied were focused on laboratory measurements rather than long-term clinical changes. Studies reported measurements of blood concentration, with the main goal being to assess how many participants achieved hormone levels within the target therapeutic range after approximately 90 days. This approach is common in androgen replacement therapy research, where the primary objective of the studies was to measure total serum testosterone levels.

Furthermore, research examined the pharmacokinetic profile of the transdermal gel, describing the compound's absorption pattern and the patterns related to maximum and average concentrations in the bloodstream. Findings contribute to the broader evidence landscape, but regulatory reviews described concerns regarding potential variability in total testosterone measurements due to assay methods and also noted that high maximum concentrations were observed in some studies.

Areas of Research Uncertainty and Study Limitations

The core evidence supporting the initial evaluation was based on a relatively short study period, and the pivotal study was non-comparative, meaning it lacked a placebo or active comparator group. This limits the ability of the study to separate the effect of the medication from other factors. Furthermore, effectiveness has not been established in males under 18 years of age, and evidence is limited for men whose low testosterone levels are solely attributed to aging, as these individuals were not the primary population studied. Data for long-term outcomes regarding specific sustained clinical endpoints are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Fortesta (FAQ)

Q: How quickly can I expect Fortesta to start working or affect my energy levels?

A: Studies and official information indicate that the benefits of testosterone therapy are not immediate. Subjective improvements like better energy and mood are typically reported within a few weeks of starting treatment, often between 3 to 6 weeks.

Full therapeutic effects on the body, such as changes in muscle mass and bone density, take several months to develop.


Q: Do I need a special test before starting Fortesta?

A: Yes, official regulatory guidelines recommend that certain laboratory tests are conducted before beginning Fortesta therapy. This pre-treatment monitoring includes checking total serum testosterone levels, PSA (Prostate-Specific Antigen), hemoglobin, hematocrit, and lipid concentrations.

These tests are also repeated periodically throughout the treatment course to support safety and proper dose adjustment.


Q: Does using Fortesta require special precautions around pets?

A: Regulatory warnings for the potential transfer of the gel primarily focus on women and children. However, the official disposal instructions explicitly state that the unused or discharged gel from priming the pump must be thrown away safely to prevent accidental exposure to both children and pets.

General caution is always important when handling any topical medication around animals.


Q: What kind of clinical changes can I expect to see in the first few months?

A: Official clinical data indicates that the most noticeable functional changes occur in the first few months. Trial data indicates that initial improvements in libido, mood, and energy may be observed during the first month.

Changes related to body composition, like increased muscle mass and decreased body fat, typically begin to become more apparent after 3 to 4 months of consistent use.


Q: What are the signs of too much testosterone absorption from Fortesta?

A: The dose is carefully adjusted based on blood tests to keep the testosterone level within the normal therapeutic range. Blood levels that exceed the upper limit may require a dose reduction.

Clinically, signs of potential over-absorption can include severe headache, blurred vision, or slurred speech, and are noted as requiring prompt consultation with a healthcare provider.


Q: Will Fortesta affect my blood pressure?

A: Yes, official labeling updates include a warning that testosterone replacement therapy can potentially cause an increase in blood pressure.

Because this may raise cardiovascular risk over time, regulatory documents recommend regular monitoring of blood pressure throughout the duration of the treatment.


Q: Can Fortesta cause mood swings or irritability?

A: According to the official adverse reaction reports, emotional changes such as mood swings, irritability, nervousness, and depression are possible side effects associated with the use of testosterone.

It is important that these effects are discussed with a healthcare provider if they occur.


Q: What happens if I forget to apply Fortesta one day?

A: Official patient information provides specific instructions for managing a missed dose. If the dose is remembered, official guidance states that the application should be performed as soon as it is remembered.

However, if it is almost time for the next scheduled application, the instruction is to skip the missed dose and return to the regular schedule. The official instruction is not to apply a double dose.


Q: What should I do if the application site skin gets irritated?

A: Application site reactions, such as redness or irritation, are noted in official sources as a common effect of the gel. Regulatory precautions state that the gel should not be applied to skin that is already cut, scraped, or irritated.

The guidance advises that irritation that persists or worsens should be reported to the prescribing doctor.


Q: Do I need to avoid certain types of exercise while using Fortesta?

A: Official patient instructions do not restrict specific types of physical exercise while using the gel. However, the instructions state that swimming, showering, or bathing is to be avoided for a minimum of 2 hours after applying Fortesta.

This waiting period is necessary to ensure the gel is fully absorbed into the skin.


Q: Is hair loss or weight change a common side effect of Fortesta?

A: Official adverse event reports list hair loss, or male pattern baldness, as a possible side effect of testosterone use. The reports also mention 'unusual weight gain or loss' in the list of adverse reactions.

Fluid retention, which is a documented risk of the therapy, can cause swelling and subsequent weight changes.


Q: Is there a risk of withdrawal symptoms when stopping Fortesta?

A: Regulatory warnings associated with the testosterone product class note the risk of withdrawal symptoms after discontinuation of therapy. These symptoms can include feelings of depression, significant fatigue, and irritability, and may continue for several weeks after the medication is discontinued.

It is important that these effects are reported to a doctor.

How should Fortesta be stored and disposed of?

How to Store and Dispose of Fortesta Gel

Fortesta Gel must be stored according to strict regulatory conditions to ensure safety and stability. The required storage environment is controlled room temperature, specifically between 68 F and 77 F (20 C to 25 C). The product must not be frozen.

Safety and Handling

Due to the hydroalcoholic formulation, Fortesta is flammable until completely dry. It must be kept away from fire, flames, or smoking during storage and use. As a controlled substance, the product must be kept in a safe place and securely stored out of the reach of children.

Disposal Instructions

To discard used Fortesta pumps and any unused product, it should be safely thrown away in household trash, taking care to prevent accidental exposure to children or pets. The gel produced during the initial pump priming must also be safely discarded down the sink or in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fortesta found in:

A-Z Index: